

## **ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES**

### **VACCINES FOR CHILDREN PROGRAM**

#### **VACCINES TO PREVENT MEASLES, MUMPS, RUBELLA, AND VARICELLA**

*The purpose of this resolution is to update guidance on the use of combined measles, mumps, rubella, and varicella vaccine.*

*VFC resolution 6/19-3 is repealed and replaced by the following:*

#### **A. Vaccines to prevent Measles, Mumps and Rubella**

##### **Eligible groups**

Children 12 months through 18 years of age (may be as young as 6 months of age in an outbreak or prior to international travel).

##### **Recommended Schedule for Measles, Mumps, and Rubella Vaccines<sup>1</sup>**

Recommended schedules for measles, mumps, and rubella vaccines can be found at:

- [Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013](#)

In addition, persons previously vaccinated with two doses of a mumps-containing vaccine<sup>2</sup> who are identified by public health as at increased risk for mumps because of an outbreak should receive a third dose of a mumps-containing vaccine to improve protection against mumps disease and related complications.

##### **Dosage Intervals for Measles, Mumps and Rubella Vaccines<sup>1</sup>**

[Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013](#)

##### **Recommended dosage**

Refer to product package inserts found at: [Vaccines Licensed for Use in the United States | FDA](#).

##### **Contraindications and Precautions**

Contraindications and Precautions can be found at:

- [Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013](#)

<sup>1</sup>Use of brand names in the resolution or links is not meant to preclude use of other licensed vaccines with similar active components. Updated 6/24/2022 based on licensure of PRIORIX (GSK) on 6/6/2022, which can be used interchangeably with M-M-M-R® II (Merck).

<sup>2</sup>As stated in Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP); includes MMR and MMR-V.

## **B. Vaccines to prevent Varicella**

### **Eligible groups**

Children at least 12 months through 18 years of age.

### **Recommended Schedule for Varicella Vaccine**

Recommended schedules for varicella vaccine can be found at:

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm)

### **Dosage Intervals for Varicella Vaccine**

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm)

### **Recommended dosage**

Refer to product package inserts found at: [Vaccines Licensed for Use in the United States | FDA](#).

### **Contraindications and Precautions**

Contraindications and Precautions can be found at:

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm).

## **C. Combined Measles, Mumps, Rubella, and Varicella Vaccine**

### **Eligible groups**

Children at least 4 years through 12 years of age.

### **Recommended Schedule for Combined Measles, Mumps, Rubella, and Varicella Vaccine<sup>3</sup>**

- For measles, mumps, rubella, and varicella vaccines given before age 4 years, the combined MMRV vaccine is not recommended. Children in this age group should receive separate measles, mumps, and rubella vaccine and varicella vaccine (MMR+V).
- For the first and second doses of measles, mumps, rubella, and varicella vaccines given at 4 years of age or older, use of MMRV vaccine generally is preferred over separate injections of its equivalent component vaccines (i.e., MMR vaccine and varicella vaccine). Considerations should include provider assessment\*, patient preference, and the potential for adverse events

\*Provider assessment should include the number of injections, vaccine availability, likelihood of improved coverage, likelihood of patient return, and storage and cost consideration.

<sup>3</sup>Use of brand names in the resolution or links is not meant to preclude use of other licensed vaccines with similar active components. Updated 6/24/2022 based on licensure of PRIORIX (GSK) on 6/6/2022, which can be used interchangeably with M-M-R®II (Merck) when MMR and varicella vaccines are administered separately.

## **Recommended dosage**

Refer to product package inserts found at: [Vaccines Licensed for Use in the United States | FDA](#).

## **Contraindications and Precautions**

Contraindications and Precautions can be found at:

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm)

[If an ACIP recommendation or notice regarding vaccination against measles, mumps, rubella, and/or varicella vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: September 19, 2025

This document can be found on the CDC website at:

[Vaccines Provided by the VFC Program | VFC Program | CDC](#)